AI is rapidly moving from experimentation and pilot projects to real-world applications across Revenue Management. This session will explore how AI can drive measurable business value in areas such as Government Pricing, Medicaid processing, contract management, compliance monitoring, and audit readiness, while also examining the broader implications of an increasingly AI-enabled regulatory environment.

As government agencies increasingly explore AI and advanced analytics in oversight and compliance activities, Revenue Management organizations must be prepared not only to use AI, but also to operate, govern, and respond effectively in an AI-enabled environment.

Our next generation of NAVLIN’s AI-driven toolset is reshaping everything when it comes to price and access. Participate in a real, hands-on workshop and explore the latest AI tools from NAVLIN.

• Discover the ability to get questions answered quickly with Ask NAVLIN and learn how you can use your favorite AI tools with NAVLIN via MCP

• Dive into NAVLIN Access Studio and see how price & access activities can be completely reimagined with AI, whether it’s BD Assessments, PICO Planning, Indication Sequencing, MFN Analysis, or generating a Price Policy – Learn how AI can perform more like a consulting assistant and not an AI chatbot

A hands-on session on using AI across HEOR work, from literature reviews to HTA submissions.

What the EU Joint Clinical Assessment (JCA) means in practice, and how to plan your evidence for it and for national HTA.

Medicaid disputes are more than an exception-management exercise. Done well, dispute management can help manufacturers identify inaccurate or ineligible claims, prevent revenue leakage, improve payment accuracy, and strengthen financial and compliance controls.

This session will examine the Medicaid dispute lifecycle from initial claim-level validation and dispute identification through research, documentation, state outreach, resolution, credits, payment, and reconciliation. Participants will explore practical approaches for prioritizing disputes based on financial impact, aging and deadlines; maintaining a complete audit trail; monitoring open and historical disputes; and using data and analytics to identify recurring issues and improve future processing.

The discussion will also consider how technology, workflow automation, and centralized dispute management can provide greater visibility into ownership, aging, financial exposure, recoveries, and resolution outcomes, helping manufacturers move from reactive dispute processing to a more proactive and strategic approach to Medicaid rebate management.

See Access Studio, NAVLIN's AI workflow platform, in action: structured workflows that combine NAVLIN data, AI and expert methodology, with sources and assumptions visible. Examples include BD assessments, PICO planning and launch sequencing.

How AI can cut business development assessments of early pipeline assets from weeks to hours, by quickly showing the likely pricing and access picture.

Preparing the organization and leadership to understand MFP details and move beyond policy interpretation and into operational execution. Learn how organizations are preparing systems, processes, contracting strategies, and cross-functional governance models to support MFP implementation.

A look at NAVLIN's latest pricing analytics, including international reference pricing (IRP) scenarios, MFN market withdrawal and loss-of-exclusivity impact.

Discussion of how ICER, payers, and CMS use evidence differently, and how to prepare for each.

What’s pressing on revenue management leaders right now, from IRA implementation and tight resources to technology modernization, and how shifting policy and regulation could change the road ahead.

How MFN has changed where and when to launch, with Europe now shaping US price exposure. Explore options like “US + 1,” confidential pricing, early access and strategic delay to protect both US and European prices.

A look at NAVLIN's AI tools for HEOR teams, with a focus on the PICO Planner for planning evidence for HTA.

A walkthrough of NAVLIN Next Gen, the upgraded Global Price Management platform: new interface, faster data capture, guided workflows, and the roadmap for features like agreement simulation and horizon scanning.

As MFN and IRP policies link prices across markets, ex-US value assessments now affect US price exposure. This session examines how HEOR can build a coherent global value story, using deliverables like global value dossiers, and inform launch sequencing decisions in a post-MFN world.

Jayson Slotnik, Partner at Health Policy Strategies, Inc.

As the U.S. drug pricing landscape continues to evolve, pharmaceutical manufacturers face growing uncertainty around policy changes, regulatory developments, and their implications for market access and pricing strategies.

This session will explore the latest developments shaping U.S. drug pricing policy, including Most Favored Nation (MFN) initiatives, 340B reform, and the broader political and regulatory environment. With a focus on what lies ahead, Jayson Slotnik will share insights into emerging policy trends, potential industry impacts, and key considerations for pharmaceutical manufacturers navigating an increasingly complex landscape.

A look at how gene therapy has evolved, from early hype to a more realistic view of what it takes to succeed, and where the field is heading next. Featuring a special guest with firsthand perspective.

Regulatory scrutiny continues to reshape how manufacturers evaluate service arrangements. Learn how evolving BF Service Fee interpretations affect ASP calculations, Government Pricing, GTN, and should be addressed in contracting strategies.

How AI is changing the way teams track and respond to pricing and access policy, with practical examples.

A country profile of Brazil, covering how pricing, HTA and reimbursement work and what to consider before launching.

With ongoing litigation, increasing audit activity, and heightened scrutiny across stakeholders, manufacturers must rethink their approach to 340B strategy, data management, and dispute resolution. 340B has evolved from a pricing program into a data-management and rebate-integrity challenge, with success increasingly dependent on claims transparency, payer data integration, and sophisticated duplicate-discount controls

From a manufacturer perspective, 340B is no longer just a chargeback or government pricing program. It has become a cross-functional ecosystem involving: Revenue Management, Government Pricing, Market Access, Contracting, Finance, IT, Legal, Compliance, PBM's, Claims Processing, Covered Entities and more.

Get the latest intel on using AI to deliver HEOR work efficiently without compromising evidence quality. We cover key guidelines, AI regulations, and HTA submission insights, show how AI should be tailored across RWE, SLRs, ITCs, and modeling, and close with a demo of our tools and key use cases.

How rare and ultra-orphan therapies reach patients through standard reimbursement, early access and named patient programs, and how MFN is shifting which route makes sense, including the Germany and Japan question.

What the completed JCA reports show about the evidence the EU expects, and how to apply those lessons to your dossier planning.

How list price becomes net price through PBM rebates, 340B and Medicaid, European clawbacks and confidential agreements. See how NAVLIN benchmarks gross-to-net across countries and models the impact of regulatory change.

MFN, PMPRB, and pCPA are all pushing Canada down the launch sequence, but how much does each one contribute? Drawing on deep experience with Canadian pharma clients and HTA, PMPRB, and pCPA negotiations, this session separates the forces at play and offers informed predictions on future access to critical therapies in Canada.

Where obesity is heading as orals and next-generation incretins arrive. Covers the evidence payers want beyond weight loss and how semaglutide's loss of exclusivity may reshape global tendering and pricing.

How to prepare evidence for Medicare negotiation, including comparative effectiveness, unmet need, and the QALY restrictions in the IRA.

How to track pricing, HTA and policy changes across your portfolio and competitors in one place. Explains the path from raw data to KPI dashboards to a managed Access Intelligence Tracker.

Learn how NAVLIN’s PICO Planner helps you map the populations, comparators and outcomes payers will expect for EU JCA and national HTA.

One Access Studio workflow in depth: assessing early assets for BD in hours, not weeks. From disease landscape and analogues to the likely price and access outlook, plus what AI does well and what stays human-led.

The EU Joint Clinical Assessment is changing how evidence is evaluated across Europe, and its lessons reach well beyond European borders. Building on the detailed JCA session, this crossover discussion explores what US teams can learn from the new process and how to apply those lessons to their own evidence strategy.

A look at how US and global pricing and access policy is likely to change by 2030, and how to prepare for it.